News | Cath Lab
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized patients with de novo three-vessel and left main coronary artery disease, according to new research. The late-breaking results from the SYNTAX Extended Survival study were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. 31-Sept. 4 in Paris, France, together with the World Congress of Cardiology and published in The Lancet.
September 25, 2019
Technology | Heart Valve Technology
Medtronic announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut Pro+ transcatheter aortic valve replacement (TAVR) system. The new-generation Medtronic TAVR system builds off the self-expanding, supra-annular Evolut TAVR platform. The Evolut Pro+ TAVR System includes four valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest indicated patient treatment range and the lowest delivery profile currently on the market, according to Medtronic. The launch comes on the heels of the FDA’s recent indication expansion for the Evolut TAVR platform to treat patients with symptomatic severe aortic stenosis at a low risk of surgical mortality, the final surgical risk category to be approved for TAVR.
September 24, 2019
Videos | Hemodynamic Support Devices
There was a 77 percent increase in survival in cardiogenic shock patients treated using a new protocol in the National ...
September 22, 2019Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News | Congenital Heart
Abbott announced approvals in Europe for two of its pediatric devices — the Masters HP 15mm rotatable mechanical heart valve and the Amplatzer Piccolo Occluder. Both devices have received CE Mark and are now available in Europe and other countries that recognize CE Mark. The new treatments, already available in the U.S., offer young pediatric patients and their families hope when no other suitable treatment option may exist.
September 20, 2019
News | Leads Implantable Devices
BioTrace Medical Inc. announced the company’s key activities at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) conference, which will take place Sept. 25-29, 2019, in San Francisco.
September 20, 2019
News | Drug-Eluting Balloons
Orchestra BioMed Inc., in partnership with Terumo Corp. announced the company has secured Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Virtue Sirolimus-Eluting Balloon (SEB) in the treatment of below-the-knee (BTK) peripheral artery disease.
September 20, 2019Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News | Heart Failure
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to consolidating cardiac care, particularly for patients with heart failure, into a convenient and comprehensive area.
September 20, 2019
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease. The late-breaking results of the ASPREE trial were presented at the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, Aug. 31-Sept. 4 in Paris. France.
September 20, 2019
Early use of an implantable cardioverter-defibrillator (ICD) after primary coronary intervention lengthens survival in patients at high risk of death after ST-segment elevation myocardial infarction (STEMI). The late-breaking results from the DAPA trial were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. 31-Sept. 4 in Paris, France, together with the World Congress of Cardiology.
September 18, 2019Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News | Blood Testing
Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour high-sensitivity cardiac troponin T (hs-cTnT) protocol is safe, according to recent research. The late-breaking results from the RAPID-TnT trial were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. 31-Sept. 4 in Paris, France, together with the World Congress of Cardiology and published in Circulation.[1] The trial also found that better strategies are needed to optimize outcomes in patients newly diagnosed with modest troponin elevations.
September 18, 2019
News | Heart Failure
AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure. The designation applies to adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).
September 18, 2019
News | CT Angiography (CTA)
The European Society of Cardiology (ESC) published new guidelines on the diagnosis and management of chronic coronary syndromes (CCS), which classifies computed tomography angiography (CTA) as a Class 1 recommendation for diagnosing CAD in symptomatic patients. The document, which is a continuation of the 2013 stable coronary artery disease (CAD) guidelines, updates the term to CCS to emphasize the dynamic nature of the disease. It was released at the 2019 ESC Congress, Aug. 31-Sept. 4 in Paris, France, and published simultaneously in the European Heart Journal.
September 17, 2019Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
Technology | Angiography
The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of angiography systems from Siemens Healthineers that permit a wide range of minimally invasive procedures to be performed in a single interventional suite. The Artis icono biplane system is engineered for optimal utilization in neuroradiology and abdominal imaging, while the Artis icono floor is a floor-mounted, single-plane system for vascular, interventional cardiology, surgical and oncology procedures. Both systems in the Artis icono family expand the reach of precision medicine.
September 17, 2019
News
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically ...
September 17, 2019
Technology | Atherectomy Devices
Rex Medical L.P. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Revolution Peripheral Atherectomy System.
September 13, 2019© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now